Gastrointestinal Effects of Semaglutide
Introduction to Semaglutide's Gastrointestinal Impact
- Semaglutide can cause dilated loops of duodenum due to its significant effects on gastric emptying and gastrointestinal motility, which may lead to food retention and bowel distension 1
- Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), significantly delays gastric emptying and affects gastrointestinal motility through several mechanisms, resulting in higher rates of retained gastric contents despite prolonged fasting periods 1
Gastric Emptying and Motility
- Patients on semaglutide have significantly higher rates of retained gastric contents, with 24.2% having increased residual gastric content compared to 5.1% in the control group (p = 0.001) 1
- Even after extended fasting (10-14 hours), solid food remains in the stomach, indicating delayed gastric emptying 1
- Higher doses of semaglutide (such as 1.7 mg weekly) appear to have stronger effects on gastric emptying 1
Complications Associated with Semaglutide
- The duodenal dilation caused by semaglutide can lead to serious complications, including aspiration risk, with multiple case reports documenting regurgitation and pulmonary aspiration in patients on semaglutide despite appropriate fasting 1
- Patients on semaglutide requiring procedures under anesthesia should be considered high risk for aspiration, and considerations should include extended fasting periods (>12 hours), rapid sequence intubation, and preparation for management of regurgitation 1
- Semaglutide is associated with severe constipation and small bowel obstruction/ileus progression 2
Patient Management and Education
- Clinicians should be aware of semaglutide's potential to cause dilated loops of duodenum and related complications, and inform patients about the importance of thorough chewing of food and avoiding large meals, particularly with high-fiber content, although this specific recommendation is not cited [3 is related to benefits, not patient education]
- Patients on chronic semaglutide therapy (median 57 months) showed higher incidence of gastric residue, indicating a potential dose-dependent effect 1